We provide services through several facility sites and in collaboration with a network of key partners, enabling us to scale our offerings to meet the needs of our sponsors. For information about any of our services, sites, or delivery methods, please contact us.


  • Boston Headquarters and Laboratory

    Invicro is operated out of our Boston Innovation District headquarters. Our contract research, image analysis, and software teams work closely with the scientists in our adjacent advanced preclinical imaging laboratory, from which we execute in vivo and ex vivo small animal imaging studies in addition to radiochemistry, pharmacology, and autoradiography services. 
  • London UK

    Prior to being acquired by Invicro in 2017, Imanova was established in 2011 and formed in an innovative alliance between the UK’s Medical Research Council, Imperial College London, King’s College London and University College London to act as a center of excellence for imaging sciences in the UK and as a conduit between academia and industry.

    Since inception, under the Imanova umbrella- over 93 clinical studies have been completed and over 30 radioligands for pre-clinical and clinical use were successfully developed and-or implemented. This puts Invicro London in a unique position to facilitate productive, mutually beneficial relationships between academia and industry.

    Today, Invicro London is a 40,300ft² purpose-built research facility offering an extensive range of preclinical services and other supporting technologies. These include but are not limited to:

    • In vitro/ex vivo characterization of novel tool compounds or drug candidates using IHC, tissue autoradiography, cell binding assays, mass spectroscopy, microscopy and FACS.
    • High end radiochemistry services for SPECT, PET and theranostic applications (ligand, therapeutic or diagnostic development)
    • Proven ability to develop, manufacture and apply a wide range of PET and SPECT ligands (> 60 tracers available for preclinical use)
    • In vivo molecular and anatomical imaging (MRI, CT, US, SPECT, PET, Optical) in a range of neuro, oncology, cardiovascular and respiratory models
    • Ready access to healthy and disease human and animal tissue

    The team comes with a strong background in drug discovery and development and significant experience in the design, execution, analysis and reporting of preclinical studies.

    Invicro London also leverages its partnership with Queen Mary University of London to access leading radiochemistry and imaging facilities to expand our service capacity and capabilities, particularly for our European customers. The facility has specialized hot-labs for synthesis of PET, SPECT and therapeutic radiochemicals and is fully equipped for radiopharmaceutical development and complimentary in vitro assays and autoradiography analysis. Pre-clinical imaging modalities include SPECT, PET, CT, Optical, Ultrasound and low-field MRI on rodents, and further in vivo capabilities include animal model development and access to other specialized techniques. Radiochemistry services are provided in partnership with Professor Stephen Mather.

    For more information on capabilities, please contact enquiries@invicro.co.uk.

  • New Haven, CT: Clinical Facility

    MNI Building

    Invicro’s New Haven, CT facility has over 36,000 square feet of research space and over 140 staff members, organized into Clinical, Chemistry, and Imaging Sciences Divisions with supporting Regulatory and Quality Assurance, Project Management, Data Management, Systems Validation, Information Technology, and Business Operations cores. The researchers here execute their work through multiple facilities, including a medicinal chemistry lab for tracer development, cGMP Radiochemistry lab for radioligand production and distribution, and an image processing lab that supports multisite coordination, site training and oversight, and data transfer management. 

  • The Translational Imaging Center

    Co-managed by Invicro and MPI Research, the TIC is located on the campus of MPI Research in Mattawan, MI. The TIC represents a combination of integrated imaging solutions offered by comprehensive imaging services in a single location and leveraging the strengths of each partner: Invicro’s molecular imaging informatics team and radiopharmaceutical group, and MPI Research’s comprehensive CRO services.
    The world’s first commercially-available cyclotron immediately contiguous with on-site vivarium facilities permits
    drug radiolabeling with short-lived isotopes and in-depth studies across a wide variety of animal models. Additional capabilities include but are not limited to all major in vivo imaging modalities: SPECT, PET, MRI, CT, Optical, DEXA, X-ray, Laser Doppler, and Ultrasonography. Complimentary assays are offered for in vivo imaging, ex vivo distrubution, animal model development and histology, 2D GLP-compliant and 3D autoradiography, and QWBA, all supported by comprehensive and collaborative scientific expertise.
  • Sanford Consortium for Regenerative Medicine

    The Sanford Consortium for Regenerative Medicine (SCRM) houses a state of the art medical imaging center, the Molecular Imaging Center at Sanford and is located in the heart of San Diego’s pharma and biotech hub in La Jolla. The SCRM is home to certain Invicro imaging operations, leveraging unique instruments, applications and west coast proximity. The site facilitates relationships and face to face contact with the company’s west coast collaborators and partners.

    The mission of Sanford Consortium for Regenerative Medicine is to advance regenerative medicine research through collaborative, multi-disciplinary interactions. This “collaboratory” enables scientists from the La Jolla Institute for Allergy & Immunology, the Salk Institute for Biological Studies, the Sanford Burnham Prebys Medical Discovery InstituteThe Scripps Research Institute, and the University of California, San Diego to work side by side in a facility specifically designed to achieve breakthrough discoveries.

    Invicro is supporting these discoveries and the efforts of pharma and biotech companies through the Molecular Imaging Center at Sanford. The facility includes rodent high field (11.7T) MRI, PET, SPECT, CT, in vivo bioluminescence and fluorescence and ultrasound. It is structured so that models can be induced within the facility or transferred in, and so that collaborators can visit and/or assist with study procedures. Specialized supporting labs include flow cytometry and an irradiation facility.

    Read more about our full capabilities here


     

  • Collaborations

    In addition to those listed above, Invicro works with a network of qualified partners across the world, allowing us to scale our service offerings across a wide range to meet specific needs.
  •  

Partnerships and Collaborations


  • MedChem Imaging

    MedChem Imaging designs imaging probes for clients engaged in pharmaceutical research and development. These agents can be radioactive drug candidates or bind targets whose occupancy assists in understanding drug action. MedChem Imaging also supplies specialty materials to the radiopharmaceutical industry.

Software Partners and Distributors


Invicro’s software is sold and distributed by our partners world-wide. VivoQuant®™, Invicro’s multi-modality post-processing suite for viewing and analyzing imaging data and iPACS®, Invicro’s image study data management platform for nonclinical to clinical applications, is currently used at more than 175 sites around the world and at more than 70% of the top pharmaceutical companies. Invicro could not support our customers worldwide without the amazing efforts by our partners.

ASPECT

AXT

Bruker

Cubresa

MagneticInsight

Mediso

MedisoaUSA

Molecubes

Sofie Biosciences

Trifoil

Trifoil